Home LiteratureArticle Details
PMID: 24686081 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes.

Cellular signalling ·Vol. 26 ·No. 7 ·2014-07-00 ·Pages 1523-31

Gimenez LE, Babilon S, Wanka L, Beck-Sickinger AG, Gurevich VV

Abstract

Based on the identification of residues that determine receptor selectivity in arrestins and the phylogenetic analysis of the arrestin (arr) family, we introduced fifteen mutations of receptor-discriminator residues in arr-3, which were identified previously using mutagenesis, in vitro binding, and BRET-based recruitment assay in intact cells. The effects of these mutations were tested using neuropeptide Y receptors Y1R and Y2R. NPY-elicited arr-3 recruitment to Y1R was not affected by these mutations, or even alanine substitution of all ten residues (arr-3-NCA), which prevented arr-3 binding to other receptors tested so far. However, NCA and two other mutations prevented agonist-independent arr-3 pre-docking to Y1R. In contrast, eight out of 15 mutations significantly reduced agonist-dependent arr-3 recruitment to Y2R. NCA eliminated arr-3 binding to active Y2R, whereas Tyr239Thr reduced it ~7-fold. Thus, manipulation of key residues on the receptor-binding surface generates arr-3 with high preference for Y1R over Y2R. Several mutations differentially affect arr-3 pre-docking and agonist-induced recruitment. Thus, arr-3 recruitment to the receptor involves several mechanistically distinct steps. Targeted mutagenesis can fine-tune arrestins directing them to specific receptors and particular activation states of the same receptor.

Keywords
Arrestins Bioluminescence resonance energy transfer (BRET) GPCRs Neuropeptide Y receptors Protein engineering Signal transduction
MeSH Terms
Animals Arrestins/genetics,metabolism COS Cells Cell Line Chlorocebus aethiops Mutation Protein Binding/genetics Receptors, Adrenergic, beta/metabolism Receptors, Dopamine/metabolism Receptors, Muscarinic/metabolism Receptors, Neuropeptide Y/metabolism
Chemicals
Arrestins Receptors, Adrenergic, beta Receptors, Dopamine Receptors, Muscarinic Receptors, Neuropeptide Y arrestin3 neuropeptide Y-Y1 receptor neuropeptide Y2 receptor
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Gimenez Luis E
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.
Babilon Stefanie
Institute of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, Leipzig University, Brüderstraße 34, D-04103 Leipzig, Germany.
Wanka Lizzy
Institute of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, Leipzig University, Brüderstraße 34, D-04103 Leipzig, Germany.
Beck-Sickinger Annette G
Institute of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, Leipzig University, Brüderstraße 34, D-04103 Leipzig, Germany.
Gurevich Vsevolod V
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: vsevolod.gurevich@vanderbilt.edu.
References (72)
72 references, click to expand
  1. Therapeutic potential of small molecules and engineered proteins.
    Handb Exp Pharmacol. 2014;219:1-12 PMID: 24292822
  2. Biased signalling and allosteric machines: new vistas and challenges for drug discovery.
    Br J Pharmacol. 2012 Mar;165(6):1659-1669 PMID: 22023017
  3. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.
    ACS Chem Biol. 2008 Sep 19;3(9):530-41 PMID: 18652471
  4. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations.
    Eur J Biochem. 1994 Nov 1;225(3):947-58 PMID: 7957231
  5. Localization and characterization of neuropeptide receptors in human colon.
    Naunyn Schmiedebergs Arch Pharmacol. 2001 Oct;364(4):291-304 PMID: 11683516
  6. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol.
    Biochem J. 1983 Jun 15;212(3):849-58 PMID: 6309155
  7. Structural diversity of G protein-coupled receptors and significance for drug discovery.
    Nat Rev Drug Discov. 2008 Apr;7(4):339-57 PMID: 18382464
  8. Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells.
    J Biol Chem. 1999 Mar 12;274(11):6831-4 PMID: 10066734
  9. Polypeptide variants of beta-arrestin and arrestin3.
    J Biol Chem. 1993 Jul 25;268(21):15640-8 PMID: 8340388
  10. Role of receptor-attached phosphates in binding of visual and non-visual arrestins to G protein-coupled receptors.
    J Biol Chem. 2012 Mar 16;287(12):9028-40 PMID: 22275358
  11. Neuropeptide Y receptors: how to get subtype selectivity.
    Front Endocrinol (Lausanne). 2013 Feb 04;4:5 PMID: 23382728
  12. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors.
    Pharmacol Rev. 1998 Mar;50(1):143-50 PMID: 9549761
  13. β-Arrestin-mediated receptor trafficking and signal transduction.
    Trends Pharmacol Sci. 2011 Sep;32(9):521-33 PMID: 21680031
  14. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer.
    Pharmacol Ther. 2011 Jul;131(1):91-113 PMID: 21439311
  15. Silent scaffolds: inhibition OF c-Jun N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant.
    J Biol Chem. 2012 Jun 1;287(23):19653-64 PMID: 22523077
  16. Detection of GPCR/beta-arrestin interactions in live cells using bioluminescence resonance energy transfer technology.
    Methods Mol Biol. 2009;552:305-17 PMID: 19513659
  17. Manipulation of very few receptor discriminator residues greatly enhances receptor specificity of non-visual arrestins.
    J Biol Chem. 2012 Aug 24;287(35):29495-505 PMID: 22787152
  18. On the origins of arrestin and rhodopsin.
    BMC Evol Biol. 2008 Jul 29;8:222 PMID: 18664266
  19. The differential engagement of arrestin surface charges by the various functional forms of the receptor.
    J Biol Chem. 2006 Feb 10;281(6):3458-62 PMID: 16339758
  20. Crystal structure of cone arrestin at 2.3A: evolution of receptor specificity.
    J Mol Biol. 2005 Dec 16;354(5):1069-80 PMID: 16289201
  21. Functional mapping of NPY/PYY receptors in rat and human gastro-intestinal tract.
    Peptides. 2002 Oct;23(10):1765-71 PMID: 12383864
  22. Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors.
    Biol Chem. 2013 Aug;394(8):921-36 PMID: 23449522
  23. Few residues within an extensive binding interface drive receptor interaction and determine the specificity of arrestin proteins.
    J Biol Chem. 2011 Jul 8;286(27):24288-99 PMID: 21471193
  24. Arrestins: ubiquitous regulators of cellular signaling pathways.
    Genome Biol. 2006;7(9):236 PMID: 17020596
  25. Custom-designed proteins as novel therapeutic tools? The case of arrestins.
    Expert Rev Mol Med. 2010 Apr 23;12:e13 PMID: 20412604
  26. Internalization determinants of the parathyroid hormone receptor differentially regulate beta-arrestin/receptor association.
    J Biol Chem. 2002 Mar 8;277(10):8121-9 PMID: 11726668
  27. Mapping the arrestin-receptor interface. Structural elements responsible for receptor specificity of arrestin proteins.
    J Biol Chem. 2004 Jan 9;279(2):1262-8 PMID: 14530255
  28. Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization.
    Cell Signal. 2009 Jan;21(1):61-8 PMID: 18845246
  29. How does arrestin respond to the phosphorylated state of rhodopsin?
    J Biol Chem. 1999 Apr 23;274(17):11451-4 PMID: 10206946
  30. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family.
    J Biol Chem. 1992 Sep 5;267(25):17882-90 PMID: 1517224
  31. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.
    Annu Rev Pharmacol Toxicol. 2012;52:179-97 PMID: 21942629
  32. Role of neuropeptide Y Y₁ and Y₂ receptors on behavioral despair in a rat model of depression with co-morbid anxiety.
    Neuropharmacology. 2012 Jan;62(1):200-8 PMID: 21803058
  33. Visual and both non-visual arrestins in their "inactive" conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm.
    J Biol Chem. 2006 Jul 28;281(30):21491-21499 PMID: 16737965
  34. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides.
    Biochem J. 1983 May 15;212(2):473-82 PMID: 6309146
  35. Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes.
    Neuropeptides. 2013 Apr;47(2):59-66 PMID: 23352609
  36. Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors?
    Trends Pharmacol Sci. 2001 Nov;22(11):560-4 PMID: 11698099
  37. Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation.
    Br J Pharmacol. 2010 Jun;160(4):892-906 PMID: 20438572
  38. Arrestin-1 expression level in rods: balancing functional performance and photoreceptor health.
    Neuroscience. 2011 Feb 3;174:37-49 PMID: 21075174
  39. Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET).
    Nat Methods. 2006 Mar;3(3):165-74 PMID: 16489332
  40. Visual arrestin interaction with rhodopsin. Sequential multisite binding ensures strict selectivity toward light-activated phosphorylated rhodopsin.
    J Biol Chem. 1993 Jun 5;268(16):11628-38 PMID: 8505295
  41. Conservation of the phosphate-sensitive elements in the arrestin family of proteins.
    J Biol Chem. 2002 Mar 15;277(11):9043-8 PMID: 11782458
  42. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.
    Pharmacol Ther. 2012 Jan;133(1):40-69 PMID: 21903131
  43. Targeting individual GPCRs with redesigned nonvisual arrestins.
    Handb Exp Pharmacol. 2014;219:153-70 PMID: 24292829
  44. Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation.
    Structure. 2001 Sep;9(9):869-80 PMID: 11566136
  45. Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors.
    J Biol Chem. 1995 Jan 13;270(2):720-31 PMID: 7822302
  46. Molecular evolution of NPY receptor subtypes.
    Neuropeptides. 2004 Aug;38(4):141-51 PMID: 15337367
  47. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications.
    Nat Biotechnol. 2002 Jan;20(1):87-90 PMID: 11753368
  48. GRK1-dependent phosphorylation of S and M opsins and their binding to cone arrestin during cone phototransduction in the mouse retina.
    J Neurosci. 2003 Jul 9;23(14):6152-60 PMID: 12853434
  49. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus.
    J Biol Chem. 2003 Mar 28;278(13):11648-53 PMID: 12538596
  50. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.
    Pharmacol Ther. 2006 Jun;110(3):465-502 PMID: 16460808
  51. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.
    J Cereb Blood Flow Metab. 1999 Feb;19(2):155-63 PMID: 10027771
  52. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2.
    J Biol Chem. 2002 Oct 4;277(40):37693-701 PMID: 12167659
  53. Structural determinants of arrestin functions.
    Prog Mol Biol Transl Sci. 2013;118:57-92 PMID: 23764050
  54. Synthetic biology with surgical precision: targeted reengineering of signaling proteins.
    Cell Signal. 2012 Oct;24(10):1899-908 PMID: 22664341
  55. Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output.
    Protein Eng Des Sel. 2006 Sep;19(9):391-400 PMID: 16857694
  56. Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation.
    J Auton Nerv Syst. 1998 May 28;70(1-2):84-91 PMID: 9686908
  57. NPY and Y receptors: lessons from transgenic and knockout models.
    Neuropeptides. 2004 Aug;38(4):189-200 PMID: 15337371
  58. The molecular acrobatics of arrestin activation.
    Trends Pharmacol Sci. 2004 Feb;25(2):105-11 PMID: 15102497
  59. The 2.8 A crystal structure of visual arrestin: a model for arrestin's regulation.
    Cell. 1999 Apr 16;97(2):257-69 PMID: 10219246
  60. The anterograde transport of the human neuropeptide Y2 receptor is regulated by a subtype specific mechanism mediated by the C-terminus.
    Neuropeptides. 2012 Dec;46(6):335-43 PMID: 23020974
  61. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains.
    J Comp Neurol. 1998 Dec 21;402(3):372-84 PMID: 9853905
  62. Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual subtypes.
    J Mol Biol. 2011 Feb 25;406(3):467-78 PMID: 21215759
  63. Beta-arrestins and cell signaling.
    Annu Rev Physiol. 2007;69:483-510 PMID: 17305471
  64. Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus.
    Cell Signal. 2008 Oct;20(10):1740-9 PMID: 18598760
  65. Ligand-induced internalization and recycling of the human neuropeptide Y2 receptor is regulated by its carboxyl-terminal tail.
    J Biol Chem. 2010 Dec 31;285(53):41578-90 PMID: 20959467
  66. A possible role of neuropeptide Y in depression and stress.
    Brain Res. 2010 Feb 16;1314:194-205 PMID: 19782662
  67. Residue 75 of interleukin-8 is crucial for its interactions with glycosaminoglycans.
    Chembiochem. 2012 Nov 26;13(17):2558-66 PMID: 23070988
  68. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation.
    J Biol Chem. 1997 Oct 31;272(44):27497-500 PMID: 9346876
  69. Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development.
    J Pept Sci. 2011 Apr;17(4):233-46 PMID: 21351324
  70. Visual arrestin binding to rhodopsin. Diverse functional roles of positively charged residues within the phosphorylation-recognition region of arrestin.
    J Biol Chem. 1995 Mar 17;270(11):6010-6 PMID: 7890732
  71. True arrestins and arrestin-fold proteins: a structure-based appraisal.
    Prog Mol Biol Transl Sci. 2013;118:21-56 PMID: 23764049
  72. An additional phosphate-binding element in arrestin molecule. Implications for the mechanism of arrestin activation.
    J Biol Chem. 2000 Dec 29;275(52):41049-57 PMID: 11024026
Article Info
Journal
Cellular signalling
Abbr.
Cell Signal
ISSN
1873-3913
Published
2014-07-00
Epub
2014-00-29
Pages
1523-31
Language
English
Region
England
NLM ID
8904683
PMCID
PMC4033671
Subset
IM
Grants
NIGMS NIH HHS · GM081756 · United States
NIGMS NIH HHS · R01 GM077561 · United States
NIGMS NIH HHS · R01 GM081756 · United States
NEI NIH HHS · EY011500 · United States
NIGMS NIH HHS · GM077561 · United States
NEI NIH HHS · R01 EY011500 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com